Skip to content

The clinical value of 3D self-healing elastic liver model for surgical training and preoperative planning: a preliminary study

The clinical value of 3D self-healing elastic liver model for surgical training and preoperative planning: a preliminary study

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300076722
Enrollment
Unknown
Registered
2023-10-17
Start date
2023-10-20
Completion date
Unknown
Last updated
2023-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cancer

Interventions

3D Printed Model group:Besides conventional preoperative planning based on contrast-enhanced CT/MRI, the investigator refers to a 3D printed model to determine the optimal surgical approach via a tria
Conventional operation group:conventional preoperative planning

Sponsors

Zhejiang Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.18-80 years old; 2.Patients with a resectable tumor in the liver; 3.Patients with contrast-enhanced CT/MRI in our center; 4.Eastern Cooperative Oncology Group Performance status score: 0; 5.Child-Pugh classification: A; 6.The Laboratory test results meet the following criteria and patients can tolerate surgery: Haemoglobin=90g/L, Neutrophil count=1.5×10?/L, Platelet count=100×10?/L, Aspartate or alanine aminotransferase=5 upper limits of normal(ULN), alkaline phosphatase=2.5 ULN, Serum albumin=30g/L, serum creatinine<1.5 ULN, International normalized ratios(INR)=2 or Prothrombin time(PT)exceed ULN=6s, Creatinine clearance=60 mL/min

Exclusion criteria

Exclusion criteria: 1.Patients with extra-hepatic metastasis; 2.Anti-cancer therapy or surgery such as radiotherapy, radiofrequency ablation in 28 days prior to the surgery; 3.Clinically significant bleeding or bleeding tendencies within 3 months prior to enrollment or on thrombolytic or anticoagulant therapy; 4.Severe lung disease (eg, pulmonary fibrosis that affects lung function, interstitial lung disease), uncontrolled diabetes mellitus (fasting blood glucose =10 mmol/L); 5.There are other unsuitable candidates for clinical trials, such as mental illness or alcohol dependence.

Design outcomes

Primary

MeasureTime frame
R0 resection rate;

Secondary

MeasureTime frame
Injury of vital vascular structures;Operation time;Blood loss;

Countries

China

Contacts

Public ContactYuhua Zhang

Zhejiang Cancer Hospital

drzhangyuhua@126.com+86 135 8803 3123

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026